Analyst Ratings for [ABBV] AbbVie Inc.

8/12/25	Resumed	Overweight	X
ABBV AbbVie Piper Sandler
$231
8/7/25	Upgrades	Neutral Outperform	X
ABBV AbbVie Daiwa Securities
$214
5/14/25	Downgrades	Buy Neutral	X
ABBV AbbVie Citigroup
$205
4/22/25	Initiated	Overweight	X
ABBV AbbVie Cantor Fitzgerald
$210
12/10/24	Resumed	Neutral	X
ABBV AbbVie BofA Securities
$191
12/5/24	Downgrades	Outperform Neutral	X
ABBV AbbVie Daiwa Securities
$180
11/22/24	Upgrades	Mkt Perform Outperform	X
ABBV AbbVie Leerink Partners
$206
11/15/24	Initiated	Outperform	X
ABBV AbbVie Wolfe Research
$205
11/4/24	Upgrades	Hold Buy	X
ABBV AbbVie Argus
10/17/24	Initiated	Mkt Perform	X
ABBV AbbVie Bernstein
$203
6/5/24	Upgrades	Hold Buy	X
ABBV AbbVie HSBC Securities
$185
5/17/24	Initiated	Overweight	X
ABBV AbbVie Cantor Fitzgerald
$200
1/29/24	Upgrades	Mkt Perform Outperform	X
ABBV AbbVie William Blair
12/18/23	Downgrades	Buy Hold	X
ABBV AbbVie HSBC Securities
12/11/23	Upgrades	Neutral Buy	X
ABBV AbbVie Goldman
11/9/23	Initiated	Hold	X
ABBV AbbVie Deutsche Bank
$150
10/30/23	Upgrades	Eq Weight Overweight	X
ABBV AbbVie Barclays
$160 $170
10/20/23	Resumed	Neutral	X
ABBV AbbVie UBS
$157 $150
9/29/23	Initiated	Outperform	X
ABBV AbbVie Raymond James
$177
7/25/23	Initiated	Mkt Perform	X
ABBV AbbVie William Blair
7/14/23	Initiated	Buy	X
ABBV AbbVie HSBC Securities
$167
4/5/23	Downgrades	Buy Hold	X
ABBV AbbVie Argus
3/1/23	Initiated	Buy	X
ABBV AbbVie Guggenheim
$172
2/22/23	Downgrades	Outperform Peer Perform	X
ABBV AbbVie Wolfe Research
2/10/23	Upgrades	Underperform Mkt Perform	X
ABBV AbbVie SVB Securities
$135 $153
11/18/22	Initiated	Outperform	X
ABBV AbbVie Credit Suisse
$170
11/8/22	Downgrades	Buy Hold	X
ABBV AbbVie Societe Generale
8/1/22	Downgrades	Overweight Neutral	X
ABBV AbbVie Atlantic Equities
$178 $162
5/23/22	Initiated	Underperform	X
ABBV AbbVie SVB Leerink
$140
5/6/22	Downgrades	Outperform Neutral	X
ABBV AbbVie Daiwa Securities
$150
2/3/22	Reiterated	Equal Weight	X
ABBV AbbVie Barclays
$133 $150
2/3/22	Reiterated	Outperform	X
ABBV AbbVie BMO Capital Markets
$153 $154
2/3/22	Reiterated	Neutral	X
ABBV AbbVie BofA Securities
$135 $138
2/3/22	Reiterated	Neutral	X
ABBV AbbVie Goldman
$117 $122
12/9/21	Resumed	Overweight	X
ABBV AbbVie Wells Fargo
$165
7/27/21	Resumed	Buy	X
ABBV AbbVie Truist
$118
4/7/21	Resumed	Outperform	X
ABBV AbbVie RBC Capital Mkts
$135
6/27/19	Upgrades	Underperform Peer Perform	X
ABBV AbbVie Wolfe Research
6/26/19	Upgrades	Mkt Perform Outperform	X
ABBV AbbVie SVB Leerink
$88
5/28/19	Initiated	Neutral	X
ABBV AbbVie Goldman
4/29/19	Upgrades	Underperform Mkt Perform	X
ABBV AbbVie BMO Capital Markets
3/25/19	Downgrades	Buy Hold	X
ABBV AbbVie Argus
1/23/19	Initiated	Neutral	X
ABBV AbbVie UBS
$91
1/3/19	Downgrades	Buy Neutral	X
ABBV AbbVie BofA/Merrill
12/26/18	Initiated	Buy	X
ABBV AbbVie Standpoint Research
10/22/18	Reiterated	Buy	X
ABBV AbbVie SunTrust
$157 $135
10/4/18	Reiterated	Buy	X
ABBV AbbVie BofA/Merrill
$107 $106
6/1/18	Downgrades	Overweight Neutral	X
ABBV AbbVie Piper Jaffray
5/30/18	Downgrades	Neutral Underperform	X
ABBV AbbVie Credit Suisse
1/30/18	Reiterated	Equal-Weight	X
ABBV AbbVie Morgan Stanley
$99 $131
1/29/18	Downgrades	Outperform Mkt Perform	X
ABBV AbbVie Leerink Partners

ABBV AbbVie Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).